Login / Signup
Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients.
C Gouynou
Laurent Peyrin Biroulet
Published in:
Alimentary pharmacology & therapeutics (2017)
Keyphrases
</>
end stage renal disease
newly diagnosed
ejection fraction
peritoneal dialysis
prognostic factors
high dose